Search company, investor...

Adaptive Biotechnologies

Founded Year




Total Raised


Date of IPO


About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ: ADPT) focuses on immuno-sequencing diagnostics, specifically in oncology. It studies and researches sequencing to profile T-Cell and B-Cell Receptors. It incorporates immuno-sequencing into clinical care for diagnosis, prognosis, and monitoring of cancer patients. The company was founded in 2009 and is based in Seattle, Washington.

Headquarters Location

1551 Eastlake Ave E Ste 200

Seattle, Washington, 98102,

United States


Missing: Adaptive Biotechnologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Adaptive Biotechnologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Adaptive Biotechnologies

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Adaptive Biotechnologies in 1 CB Insights research brief, most recently on Aug 17, 2022.

Expert Collections containing Adaptive Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adaptive Biotechnologies is included in 6 Expert Collections, including Medical Devices.


Medical Devices

12,357 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,901 items

Adaptive Biotechnologies Patents

Adaptive Biotechnologies has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins



Latest Adaptive Biotechnologies News

Looking Into Adaptive Biotechnologies's Return On Capital Employed - Adaptive Biotechnologies (NASDAQ:ADP

Nov 25, 2022

Benzinga By Benzinga Insights According to data from Benzinga Pro, during Q3, Adaptive Biotechnologies's ADPT reported sales totaled $47.83 million. Despite a 12.99% increase in earnings, the company posted a loss of $45.32 million. Adaptive Biotechnologies collected $43.66 million in revenue during Q2, but reported earnings showed a $52.08 million loss. Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Adaptive Biotechnologies posted an ROCE of -0.09%. AD AD It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

Adaptive Biotechnologies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Adaptive Biotechnologies Rank

Adaptive Biotechnologies Frequently Asked Questions (FAQ)

  • When was Adaptive Biotechnologies founded?

    Adaptive Biotechnologies was founded in 2009.

  • Where is Adaptive Biotechnologies's headquarters?

    Adaptive Biotechnologies's headquarters is located at 1551 Eastlake Ave E, Seattle.

  • What is Adaptive Biotechnologies's latest funding round?

    Adaptive Biotechnologies's latest funding round is IPO.

  • How much did Adaptive Biotechnologies raise?

    Adaptive Biotechnologies raised a total of $460.55M.

  • Who are the investors of Adaptive Biotechnologies?

    Investors of Adaptive Biotechnologies include Microsoft, Viking Global Investors, Matrix Capital Management, LabCorp, Casdin Capital and 11 more.

  • Who are Adaptive Biotechnologies's competitors?

    Competitors of Adaptive Biotechnologies include immunai, Strata Oncology, SynergEyes, Light Sciences Oncology, Corpora Systems and 13 more.

Compare Adaptive Biotechnologies to Competitors

Holochip Logo

Holochip manufactures adaptive polymer singlet lenses that allow adjustability of focal length without changing the location of the lens. This flexibility aims to provide a compact, rugged and reliable solution for utilizing and manipulating light.

TrueVision Systems

TrueVision Systems, dba TrueVisions 3D Surgical, provides digital 3D visualization and guidance for microsurgery. The company has developed an intelligent, real-time, 3D surgical visualization and computer-aided guidance platform. TrueVision combines 3D visualization and guidance software applications focused on improving accuracy, efficiency, and outcomes for both surgeons and patients. The company is developing 3D guidance applications for microsurgery to improve surgical efficiencies and patient outcomes. The Refractive Cataract Toolset is a computer-aided software for astigmatic correction and advanced IOL positioning.


Luminetx Corporation discovers, develops, and commercializes bioscience technologies.

SynergEyes Logo

SynergEyes develops and manufactures hybrid contact lens and its goal is to combine the superior visual acuity of a rigid gas permeable lens with the comfort of a soft contact lens. The SynergEyes hybrid contact aims to offer a stable, high oxygen permeable rigid center that delivers consistent, crisp, clear vision while the outer skirt provides all comfort of a soft lens. The company was founded in 2001 and is based in Carlsbad, California.


InnerOptic is a medical device startup focused on the integration of 3D ultrasound imagery and surgery.

eSight Logo

eSight creates electronic glasses that restore or enhance sight for individuals living with vision loss. Worn comfortably like a normal pair of glasses or with prescription lenses built-in, they allow a person with low vision to see in virtually the same manner as someone who is fully-sighted can. The company's SPEX enhances vision for precision tasks, allowing users to pan and zoom the real world or streamed images, and brings critical information to the point of task without overwriting or obstructing natural vision for full situational awareness and mobility.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.